3 Jul 2019 07:00
July 3, 2019
Verseon Corporation
("Verseon" or the "Company")
Additional Listing & Total Voting Rights
Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 8,476 new shares of common stock ("Common Shares") of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance").
The 8,476 Common Shares were issued to Dr. Hecht, a non-executive Directors of the Company, in relation to the payment of his Director's fees. Following the Issuance, Dr. Hecht will hold 115,370 Common Shares, representing 0.07% of the Company's issued share capital.
The 8,476 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on July 8, 2019 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 159,737,905 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,694,988. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
-Ends-
For further information, please contact
Verseon Corporation | www.verseon.com |
Sebastian Wykeham / Tina Schlafly | +1 (510) 225 9000 |
Arden Partners (NOMAD and Joint Broker) |
|
Ruari McGirr / Ciaran Walsh/ Dan Gee-Summons (Corporate Finance) / Fraser Marshall (Equity Sales) | +44 (0) 20 7614 5900 |
Cantor Fitzgerald Europe (Joint Broker) |
|
Phil Davies | +44 (0) 20 7894 7000 |
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers) |
|
Henry Harrison-Topham / Jamie Hooper | +44 (0) 20 7466 5000 |
For trade and pharma media enquiries, please contact
Vane Percy & Roberts |
|
Simon Vane Percy | +44 (0) 1737 821 890 |
1
| Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| Dr. Thomas Hecht | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Non-Executive Chairman | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Verseon Corporation | ||||
b)
| LEI
| 213800CB2DUHDL6EPW12 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Restricted stock grant of Common Shares of par value $0.001
ISIN: USU9221J1171
| ||||
b)
| Nature of the transaction
| Vesting of restricted stock units | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
|
8,476
- | ||||
e)
| Date of the transaction
| 30 June 2019 | ||||
f)
| Place of the transaction
| N/a | ||||
VERS.L (VERS)